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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and its
prevalence is likely to rise even further. To help understand the pathogenesis and early prevention of progressive
NAFLD, this large-scale study was designed to explore the potential association between homocysteine and the
prevalence of NAFLD.
Methods: A total of 7203 subjects aged 18 years or older were enrolled in this cross-sectional study. The association of
homocysteine with the prevalence of NAFLD, in the total sample and stratified by subgroups, was examined using
multiple logistic regression analyses.
Results: Subjects in the higher quartiles of homocysteine had a higher prevalence of NAFLD. After multivariate
adjustment, the odds ratio (OR) for NAFLD in the highest compared with the lowest quartile of homocysteine was 2.08
(95% confidence interval [CI] 1.61, 2.67). Moreover, in the subgroup analyses, we found an effect modification by gender,
body mass index (BMI) and smoking status on the association between homocysteine and the prevalence of
NAFLD (P for interaction: 0.001, 0.002 and <0.001, respectively). A stronger association was observed in female,
obese and non-smoking adults than in male, normal weight and smoking subjects.
Conclusion: Homocysteine was significantly associated with the prevalence of NAFLD, particularly in female,
obese or non-smoking adults.
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Background
Non-alcoholic fatty liver disease (NAFLD), which en-
compasses a spectrum of conditions associated with lipid
deposition in hepatocytes, is the most common liver
disease. Worldwide, the overall prevalence of NAFLD
diagnosed by imaging was 25.2% with the highest preva-
lence rates were reported from South America (30.5%)
and the Middle East (31.8%) [1]. In China, NAFLD
affects over a quarter of the population, and its preva-
lence is still increasing rapidly as a result of considerable
changes in lifestyle and aging [2–4]. NAFLD is often
associated with metabolic risk factors, such as obesity,
type two diabetes, dyslipidemia, and insulin resistance.
In addition to hepatic complications, NAFLD is also as-
sociated with serious systemic consequences. NAFLD
has been widely accepted to significantly increase the
morbidity and mortality of cardiovascular diseases [5–7].
Homocysteine is a sulfhydryl-containing amino acid
mainly produced and catabolized in the liver [8, 9]. A
growing body of evidence shows that homocysteine me-
diates cardiovascular problems by its adverse effects on
cardiovascular endothelium and smooth muscle cells
[10]. Moreover, homocysteine can alter intracellular lipid
metabolism and may promote hepatic fat accumulation
[11, 12]. Thus, it is plausible that homocysteine could be
an effective target for preventing the progression of
NAFLD and its related cardiovascular complications.
However, only a few studies have explored the associ-
ation between homocysteine and the prevalence of
NAFLD, and the answer remains controversial [13–15].
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In addition, it is also important to confirm whether these
associations are moderated by other closely related
factors, such as gender and body mass index (BMI), as
substantial differences exist with regard to the metabol-
ism of homocysteine between males and females as well
as among BMI groups [10, 16].
In this study, we performed a cross-sectional analysis
to determine whether elevated homocysteine was associ-
ated with an increased prevalence of NAFLD in Chinese
adults. Moreover, we also explored the possible effect
modification by other related factors on the association
between homocysteine and the prevalence of NAFLD.
Methods
Study population
The Health Management Center of Third Xiangya Hospital
is one of China’s largest examination centers, mainly
servicing individuals from hundreds of institutions in
Changsha. In this cross-sectional study, we consecutively
recruited 13,916 individuals who underwent a health exam-
ination in the center from January 2014 to December 2014.
The inclusion criteria were: 1) aged 18 years or older; 2)
availability of abdominal ultrasonography examination; 3)
and undergoing plasma homocysteine measurements.
Questionnaires were answered by all of the enrolled sub-
jects to collect information on medical history, alcohol
consumption, cigarette smoking, etc. In order to remove
the effect of alcohol on the fatty liver, we excluded subjects
with excessive alcohol consumption (n = 1629) as well as
those with incomplete information on alcohol consumption
(n = 4451). As a result, 7836 subjects were included. Of
these kept subjects, 565 subjects were diagnosed or self-
reported to have viral hepatitis, schistosomiasis liver
disease or other chronic liver diseases, 9 subjects were
self-reported taking steatogenic medications, 12 subjects
were self-reported taking vitamin B or folic acid, and 47
subjects had no available data on height or body weight;
all of these patients were excluded from our study. Finally,
7203 subjects were screened and deemed eligible for the
present study.
This study was approved by the Medical Ethics
Committee of Third Xiangya Hospital. All of the experi-
ments in this study were performed according to the guide-
lines from the Helsinki Declaration, and written informed
consent was obtained from all participants.
Data collection and measurements
Information on age, gender, alcohol consumption, cigarette
smoking, physical activity, education level, and medical
history were obtained from standardized questionnaires
through face-to-face interviews. Alcohol consumption was
evaluated with questions regarding the types of alcoholic
beverages, the frequency of alcohol consumption per week
and the usual amount consumed per occasion. Subjects
who reported alcohol consumption ≥140 g/week for men
and ≥70 g/week for women were deemed to have excessive
alcohol consumption [17]. Smoking was recorded as daily
(at least one cigarette/day), occasional (less than one
cigarette/day), former (having quit for at least 6 months), or
never smoking. For our analyses, only two categories were
considered: current smoking (daily and occasional smok-
ing) and non-smoking (never and former smoking) [18].
Physical activity was defined as the frequency of physical
activity during leisure time and was scored as inactive (1–2
times per week), moderate (3–5 times per week), or active
(≥6 times per week).
Standing height and body weight were measured with-
out shoes or thick clothing, and BMI was calculated as
body weight in kilograms divided by height in meters
squared. Blood pressure (BP) was measured in the sitting
position after a 10-min rest period using an appropriately
sized cuff and a corrected mercury sphygmomanometer.
Systolic BP and diastolic BP were each measured twice in
this study, with a 30 s interval. If the two measurements
differed by >5 mmHg, BP was re-measured. Finally, the
BP was calculated as the average of the three measure-
ments. Hypertension was defined by the presence of any
of the following: systolic BP ≥140 mmHg and/or diastolic
BP ≥90 mmHg, a history of hypertension, or current use
of antihypertensive agents.
Venous blood sampling was performed after overnight
fasting for 8–12 h, and the blood glucose, alanine trans-
aminase (ALT), total bilirubin (TBIL), albumin (ALB),
platelet count (PLT), serum uric acid, triglyceride (TG),
total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), high-sensitivity C-reactive protein (hs-CRP),
serum creatinine and homocysteine levels were deter-
mined using standard laboratory methods. The laboratory
methods were consistent throughout the study period. All
blood samples were tested using an auto-analyzer (Hitachi
7600-110; Hitachi, Tokyo, Japan) at the central laboratory
of Third Xiangya Hospital. Diabetes was diagnosed by
fasting blood glucose ≥7.0 mmol/L, a history of diabetes,
or current use of hypoglycemic agents [19].
Definition of non-alcoholic fatty liver disease
Hepatic steatosis was diagnosed upon abdominal ultra-
sonography by experienced and trained radiologists who
were blinded to the subjects’ clinical diagnoses and bio-
chemical tests. Positive abdominal ultrasound images
included: diffusely increased liver near field ultrasound
echo (‘bright liver’), liver echo greater than kidney,
vascular blurring and the gradual attenuation of far field
ultrasound echo. Subjects with at least two of the abnor-
mal findings listed above were diagnosed with hepatic
steatosis [17, 20]. Because all of the subjects with
secondary causes for hepatic steatosis such as excessive
alcohol consumption, viral hepatitis, or use of steatogenic
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medication were excluded from our study, NAFLD was
defined by the presence of hepatic steatosis [20, 21].
Statistical analysis
In order to derive a deeper understanding of the rela-
tionship between serum homocysteine levels and the
prevalence of NAFLD, all of the study subjects were
classified into four groups by their quartiles of homo-
cysteine (Q1: <5.1 μmol/L, Q2: 5.1 to <7.1 μmol/L, Q3:
7.1 to <9.9 μmol/L, Q4: ≥9.9 μmol/L). Basic characteris-
tics of the study subjects were presented as the mean ±
standard deviation (SD) or median (interquartile range)
for continuous variables and as numbers with percent-
ages for categorical variables. Variables that displayed a
skewed distribution (age, ALT, TBIL, TG, hs-CRP and
homocysteine) were log transformed to normal before
analysis.
For continuous variables, one-way ANOVA with a
post-hoc t-test with Bonferroni correction for multiple
comparisons was used to compare differences between
the quartiles of serum homocysteine. For categorical var-
iables, differences between group frequencies were
assessed with the Pearson χ2 test. The odds ratio (OR)
with 95% confidence intervals (CIs) were calculated
using logistic regression to determine the risk of NAFLD
for each quartile of homocysteine, with the lowest quartile
regarded as the reference category. Moreover, age, gender,
BMI (categorized as normal: <24 kg/m2, overweight: 24 to
<28 kg/m2, and obesity: ≥28 kg/m2, as based on the Work-
ing Group on Obesity in China guidelines [22]), current
smoking, hypertension, and diabetes were evaluated to
assess whether there was any significant interaction be-
tween these variables and the relationship between homo-
cysteine levels and the prevalence of NAFLD.
All of the analyses were performed using IBM SPSS
Statistics Ver. 22.0 (IBM Co., Armonk, NY, USA), and
P < 0.05 was considered to indicate statistical signifi-
cance. Post-hoc Bonferroni correction was used for
multiple comparisons.
Results
Characteristics of the study subjects
Of the 7203 subjects, 2370 (32.9%) were diagnosed with
NAFLD, and the mean homocysteine level was 7.0 (5.0,
9.9) μmol/L. The characteristics of the study population
in total and according to homocysteine quartiles are dis-
played in Table 1. When compared with subjects in Q1
group, those with higher homocysteine levels were more
likely to be older, male, and current smokers, and they
tended to have increased prevalence of hypertension as
well as higher levels of BMI, ALT, TBIL, ALB, serum
uric acid, TG, hs-CRP and creatinine. In addition, the
frequency of physical activity, prevalence of drinking and
diabetes, and levels of education, PLT, TC, and HDL-C
were also significantly different among the homocysteine
quartiles.
Association between homocysteine and non-alcoholic
fatty liver disease
As shown in Table 1, the prevalence of NAFLD progres-
sively increased in the higher quartiles of homocysteine
(19.8, 28.3, 37.7, and 46.6%, respectively). Table 2 shows
the multiple adjusted association between the quartiles of
homocysteine and NAFLD. In the adjusted model 1, after
adjustment for age, the OR for NAFLD in the highest
compared to the lowest quartile of homocysteine was 3.10
(95% CI 2.67, 3.59). After further adjustment for gender,
BMI, current smoker, physical activity, education, drink-
ing, hypertension, diabetes, uric acid, ALT, TBIL, ALB,
PLT, TG, TC, HDL-C, hs-CRP, and creatinine, the risk for
NAFLD increased across the homocysteine quartiles, and
the OR in the highest quartile compared with the lowest
quartile was 2.08 (95% CI 1.61, 2.67). Similar results were
also observed when homocysteine was considered as a
continuous exposure variable (per SD increment, Table 2).
Subgroup analyses
To determine the effect of potential confounding factors,
the associations between quartiles of homocysteine and
NAFLD were further investigated among subgroups. As
a result, we determined that the association differed
significantly according to gender, BMI category and
smoking status (P for interaction: 0.001, 0.002 and
<0.001, respectively; Fig. 1). No effect modifications by
age, hypertension, or diabetes on the association
between homocysteine and NAFLD were observed (all P
for interaction >0.05).
The subgroup analysis by gender indicated that homo-
cysteine was strongly associated with NAFLD in females
but was weaker in males (Fig. 1). After multivariate
adjustment, the OR of having NAFLD with per SD in-
crement of log homocysteine was 1.67 (95% CI 1.40,
1.99) in females, whereas the corresponding OR was
1.14 (95% CI 1.02, 1.27) in males. Similarly, obesity and
non-smoking status were also related to an enhanced
association between homocysteine and the prevalence of
NAFLD (Fig. 1).
Discussion
In this cross-sectional study, the main finding was that
elevated homocysteine levels were positively associated
with the prevalence of NAFLD in Chinese adults.
Besides, in the subgroup analyses, an effect modification
by gender, BMI and smoking on the association was
found. A stronger association of homocysteine with the
prevalence of NAFLD was observed in female, obese and
non-smoking adults than in male, normal weight and
smoking subjects.
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Over the past decade, accelerating interest has devel-
oped in the relationship between homocysteine and the
prevalence of NAFLD. On one hand, homocysteine is a
sulfhydryl-containing amino acid mainly produced and
catabolized in the liver [8, 9]. It is plausible that, in the
presence of liver damage, alterations of serum homocyst-
eine levels may occur. On the other hand, elevated
homocysteine may conversely promote the progression
of liver damage. Indeed, Yao et al. [23] recently found
that hyperhomocysteinemia could promote hepatic stea-
tosis in mice through activation of the aryl hydrocarbon
receptor/CD36 pathway. According to several experi-
mental studies, hepatic lipid accumulation was induced
in different models of hyperhomocysteinemia [24–26].
In a study of pediatric NAFLD, Pastore et al. [27] found
that homocysteine strongly correlated with the severity of
liver damage. These previous studies suggested that
homocysteine was associated with NAFLD progression.
Meanwhile, accumulating evidence has demonstrated that
homocysteine is an independent risk factor for cardiovas-
cular diseases such as stroke [28, 29] and ischemic heart
disease [30, 31], which suggests that homocysteine may
mediate the association between NAFLD and cardiovascu-
lar diseases [32]. Thus, it is plausible that homocysteine
might be an effective target for preventing NAFLD pro-
gression and its related cardiovascular complications.
Although several clinical studies have reported the
association between homocysteine and the prevalence of
Table 1 Characteristics of the study population in total and according to homocysteine quartiles
Variables Total Quartiles of Homocysteine P value
Q1 (<5.1) Q2 (5.1 to <7.1) Q3 (7.1 to <9.9) Q4 (≥9.9)
N 7203 1876 1815 1697 1815
Homocysteine (μmol/L)a 7.0 (5.0, 9.9) 4.0 (3.9, 5.0) 6.0 (5.9, 7.0)# 8.3 (7.9, 9.0)# 12.3 (10.8, 14.9)# <0.001
Age (years)a 49.0 (40.0, 59.0) 46.0 (38.0, 52.0) 49.0 (40.0, 57.0)# 48.0 (39.0, 58.0)# 53.0 (42.0, 70.0)# <0.001
Male, % 3801 (52.8) 477 (25.4) 794 (43.7)# 1024 (60.3)# 1506 (83.0)# <0.001
BMI (kg/m2) 24.1 ± 3.3 23.6 ± 3.2 24.0 ± 3.2# 24.2 ± 3.2# 24.7 ± 3.3# <0.001
Current smoker, % 1698 (24.0) 284 (15.5) 364 (20.6)# 439 (26.2)# 611 (33.9)# <0.001
Physical activity <0.001
Inactive, % 3590 (53.6) 991 (58.7) 888 (54.0) 898 (55.6) 813 (46.4)
Moderate, % 1769 (26.4) 461 (27.3) 472 (28.7) 408 (25.2) 428 (24.4)
Active, % 1342 (20.0) 235 (13.9) 284 (17.3) 310 (19.2) 513 (29.2)
Education <0.001
Illiteracy/Primary, % 282 (4.1) 74 (4.2) 62 (3.6) 72 (4.4) 74 (4.2)
Middle school, % 2234 (32.5) 683 (38.3) 612 (35.8) 479 (29.4) 460 (26.2)
College or higher, % 4361 (63.4) 1026 (57.5) 1035 (60.6) 1081 (66.2) 1219 (69.5)
Drinking, % 1459 (20.3) 252 (13.4) 276 (15.2) 412 (24.3)# 519 (28.6)# <0.001
Hypertension, % 2144 (30. 0) 342 (18.4) 485 (27.0)# 507 (30.1)# 810 (45.0)# <0.001
Diabetes, % 543 (7.5) 115 (6.1) 132 (7.3) 127 (7.5) 169 (9.3)# 0.002
ALT (U/L)a 21.0 (15.0, 30.0) 18.0 (14.0, 26.0) 20.0 (15.0, 29.0)# 22.0 (17.0, 33.0)# 23.0 (17.0, 33.0)# <0.001
TBIL (μmol/L)a 14.8 (12.1, 18.3) 14.1 (11.6, 17.1) 14.7 (11.9, 18.2)# 15.1 (12.3, 18.8)# 15.6 (12.5, 19.1)# <0.001
ALB (g/L) 46.5 ± 2.6 46.2 ± 2.5 46.6 ± 2.5# 46.8 ± 2.6# 46.5 ± 2.8# <0.001
PLT (109/L) 213.1 ± 55.0 218.2 ± 55.0 215.8 ± 55.5 215.5 ± 56.7 202.9 ± 51.6# <0.001
Uric acid (μmol/L) 297.7 ± 92.2 263.8 ± 84.5 289.6 ± 91.9# 300.5 ± 86.0# 338.3 ± 90.0# <0.001
TG (mmol/L)a 1.3 (0.9, 1.9) 1.2 (0.8, 1.7) 1.3 (0.9, 1.8)# 1.3 (0.9, 2.0)# 1.4 (1.0, 2.0)# <0.001
TC (mmol/L) 5.2 ± 1.0 5.1 ± 1.0 5.2 ± 1.0# 5.2 ± 1.0# 5.1 ± 1.0 0.001
HDL-C (mmol/L) 1.6 ± 0.4 1.7 ± 0.4 1.6 ± 0.4# 1.6 ± 0.4# 1.5 ± 0.4# <0.001
hs-CRP (mg/L)a 1.1 (0.6, 1.9) 0.9 (0.5, 1.7) 1.1 (0.6, 2.0)# 1.1 (0.6, 2.0)# 1.2 (0.7, 2.1)# <0.001
Creatinine (μmol/L) 67.2 ± 22.0 57.4 ± 12.2 64.6 ± 18.9# 67.9 ± 15.0# 79.4 ± 30.7# <0.001
Prevalence of NAFLD, % 2370 (32.9) 372 (19.8) 513 (28.3)# 640 (37.7)# 845 (46.6)# <0.001
Abbreviations: BMI body mass index, ALT alanine transaminase, TBIL total bilirubin, ALB albumin, PLT platelet count, TG triglyceride, TC total cholesterol, HDL-C high-
density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein
aVariables were log transformed before analysis
#P <0.05, in comparison with the reference group (quartile 1). P values were corrected by Bonferroni’s method due to multiple testing
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NAFLD, the results were inconclusive. According to a
case-control study including 50 patients with non-
alcoholic steatohepatitis (NASH) and 30 healthy subjects,
serum homocysteine levels were identified significantly
higher in patients with NASH vs. controls [15]. Won et al.
[33] found that the uppermost quartile of homocysteine in
men was significantly associated with a 6.78-fold in-
creased OR for NAFLD. Consistent with these findings,
the positive association of serum homocysteine levels
with NAFLD was shown in a meta-analysis by Dai et al.
[34], which was based on eight studies (six cross-
sectional and two case-control), totaling 935 partici-
pants (397 NAFLD cases and 538 controls). In contrast,
another study suggested that serum homocysteine
levels were not associated with NAFLD [35]. Further-
more, most related studies did not assess the independ-
ent risk of homocysteine with adjusting for potential
confounders such as BMI, liver enzymes and dyslipid-
emia, and the relatively small number of subjects in
these studies also made it difficult to draw definitive
conclusions. The results of our study using a large sam-
ple with adjustment for multiple confounders support a
Fig. 1 Association between homocysteine and non-alcoholic fatty liver disease in selected subgroups. Homocysteine is presented with a continuous
scale (per SD increment of log homocysteine). Multiple logistic regression and interaction adjusted for agea, gender, body mass index, current smoker,
physical activity, education, drinking, hypertension, diabetes, uric acid, alanine transaminasea, total bilirubina, albumin, platelet count, triglyceridea, total
cholesterol, high-density lipoprotein cholesterol, high-sensitivity C-reactive proteina, and creatinine. aVariables were log transformed before analysis
Table 2 Odds ratios for the association between serum homocysteine and the prevalence of non-alcoholic fatty liver disease
Homocysteine
(μmol/L)
N = 7023 OR (95% CI)
Model 1 Model 2 Model 3
Quartiles
Q1 (<5.1) 1876 1 (Ref) 1 (Ref) 1 (Ref)
Q2 (5.1 to <7.1) 1815 1.52 (1.30, 1.77) 1.44 (1.18, 1.74) 1.32 (1.04, 1.67)
Q3 (7.1 to <9.9) 1697 2.38 (2.04, 2.76) 1.90 (1.57, 2.30) 1.75 (1.39, 2.22)
Q4 (≥9.9) 1815 3.10 (2.67, 3.59) 1.91 (1.57, 2.32) 2.08 (1.61, 2.67)
P for trend <0.001 <0.001 <0.001
Per SD increment 7023 1.47 (1.40, 1.55) 1.18 (1.10, 1.27) 1.25 (1.15, 1.37)
P value <0.001 <0.001 <0.001
Model 1: adjusted for agea; Model 2: further adjusted for gender, body mass index, current smoker, physical activity, education, drinking; Model 3: further adjusted
for hypertension, diabetes, uric acid, alanine transaminasea, total bilirubina, albumin, platelet count, triglyceridea, total cholesterol, high-density lipoprotein choles-
terol, high-sensitivity C-reactive proteina, creatinine.
Per SD increment represents 1 SD increment of log homocysteine.
aVariables were log transformed before analysis
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positive association between homocysteine and the
prevalence of NAFLD.
Our study also explored a possible effect modification
by other related factors, such as gender and BMI, on the
association between homocysteine and the prevalence of
NAFLD. We concluded that the association was stronger
in female, obese or non-smoking adults. In contrast to our
study, a recent study found that homocysteine was closely
associated with the prevalence of NAFLD in men but not
in women [33]. However, only approximately 30 subjects
with a small number of events were categorized in each
quartile of homocysteine in that study, and it was hard to
conduct a stable estimate for NAFLD. Interestingly, sev-
eral previous studies have also suggested that serum
homocysteine-related risk of cardiovascular diseases prone
to be significant in women, but not in men [36–38]. Un-
fortunately, to date, the underlying mechanism of such
gender-specific differences remains unknown. Obesity was
reported to be associated with two key liver enzymes in-
volved in homocysteine metabolism and may affect the ca-
tabolism of homocysteine in liver damage [39]. Our study
firstly showed that the association between homocysteine
and NAFLD was strengthened by obesity. Moreover, our
study found that the association between homocysteine
and NAFLD was attenuated in current smokers. Cigarette
smoking is known to be associated with oxidative stress,
the proinflammatory response, and fatty acid synthesis,
which may have caused the phenomenon observed in our
study [40, 41]. However, further studies are required to
validate and explicate the effect modification noted in our
study.
The present study has several limitations. First, this
cross-sectional study was unable to explain the causal re-
lationship; thus, further prospective cohort studies and
intervention trials should be undertaken to establish a
causal association between homocysteine and the preva-
lence of NAFLD. Second, the presence of hepatic steatosis
was assessed by ultrasonography rather than liver biopsy
pathology. Nonetheless, ultrasonography has been widely
accepted for population-based studies due to its safety,
economical cost and reasonable accuracy [21, 42].
Conclusions
In conclusion, we found that homocysteine was signifi-
cantly associated with the prevalence of NAFLD, particu-
larly in female, obese or non-smoking adults. Further
research is needed to determine whether the associations
found in this study are causal and whether homocysteine-
lowering therapy can be used to prevent progressive
NAFLD and its related cardiovascular complications, par-
ticularly for female, obese and non-smoking adults.
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